Co-Diagnostics, Inc. Strengthens Zika Customer Base in Caribbean Basin

Sales expected upon successful performance evaluation and validation SANDY, Utah CODX, (BUSINESS WIRE) Co-Diagnostics, Inc. (NASDAQ: CODX) (“Co-Diagnostics” or the “Company”), a molecular diagnostics company with a unique, proprietary platform for the development of diagnostic tests, announced today that they have strengthened relationships with key regional customers throughout the Caribbean basin to purchase the Company’s Zika virus diagnostic. The potential customer base includes laboratories, regional health ministries, and hospitals interested in offering a state-of-the-art molecular diagnostic for the Zika virus to their
http://bit.ly/2vdlpOI